Show simple item record

dc.contributor.authorStene, Guro Birgitte
dc.contributor.authorBalstad, Trude Rakel
dc.contributor.authorLeer, Anne Silja Mäkitalo
dc.contributor.authorBye, Asta
dc.contributor.authorKaasa, Stein
dc.contributor.authorFallon, Marie T.
dc.contributor.authorLaird, Barry J
dc.contributor.authorMaddocks, Matthew
dc.contributor.authorSolheim, Tora Skeidsvoll
dc.date.accessioned2019-12-11T07:53:40Z
dc.date.available2019-12-11T07:53:40Z
dc.date.created2019-12-03T20:05:52Z
dc.date.issued2019
dc.identifier.citationCancers. 2019, 11 (1925), .nb_NO
dc.identifier.issn2072-6694
dc.identifier.urihttp://hdl.handle.net/11250/2632565
dc.description.abstractBackground: Muscle mass and physical function (PF) are common co-primary endpoints in cancer cachexia trials, but there is a lack of data on how these outcomes interact over time. The aim of this secondary analysis of data from a trial investigating multimodal intervention for cancer cachexia (ClinicalTrials.gov: NCT01419145) is to explore whether changes in muscle mass and PF are associated with weight loss and cachexia status at baseline. Methods: Secondary analysis was conducted using data from a phase II randomized controlled trial including 46 patients with stage III–IV non-small cell lung cancer (n = 26) or inoperable pancreatic cancer (n = 20) due to commence chemotherapy. Cachexia status at baseline was classified according to international consensus. Muscle mass (assessed using computed tomography (CT)) and PF outcomes, i.e., Karnofsky performance status (KPS), self-reported PF (self-PF), handgrip strength (HGS), 6-minute walk test (6MWT), and physical activity (PA), were measured at baseline and after six weeks. Results: When compared according to cachexia status at baseline, patients with no/pre-cachexia had a mean loss of muscle mass (−5.3 cm2, p = 0.020) but no statistically significant change in PF outcomes. Patients with cachexia also lost muscle mass but to a lesser extent (−2.8 cm2, p = 0.146), but demonstrated a statistically significant decline in PF; KPS (−3.8 points, p = 0.030), self-PF (−8.8 points, p = 0.027), and HGS (−2.7 kg, p = 0.026). Conclusions: Weight loss history and cachexia status at baseline are of importance if one aims to detect changes in PF outcomes in cancer cachexia trials. To improve the use of co-primary endpoints that include PF in future trials, outcomes that have the potential to detect change relative to weight loss should be investigated further.nb_NO
dc.language.isoengnb_NO
dc.publisherMDPInb_NO
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleDeterioration in Muscle Mass and Physical Function Differs According to Weight loss History in Cancer Cachexianb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionpublishedVersionnb_NO
dc.source.pagenumber14nb_NO
dc.source.volume11nb_NO
dc.source.journalCancersnb_NO
dc.source.issue1925nb_NO
dc.identifier.doi10.3390/cancers11121925
dc.identifier.cristin1756272
dc.description.localcode© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).nb_NO
cristin.unitcode194,65,30,0
cristin.unitcode194,65,15,0
cristin.unitnameInstitutt for nevromedisin og bevegelsesvitenskap
cristin.unitnameInstitutt for klinisk og molekylær medisin
cristin.ispublishedtrue
cristin.fulltextpostprint
cristin.qualitycode1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal